Equities

IOL Chemicals and Pharmaceuticals Ltd

IOL Chemicals and Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)486.45
  • Today's Change4.95 / 1.03%
  • Shares traded536.01k
  • 1 Year change-2.67%
  • Beta1.3706
Data delayed at least 15 minutes, as of Sep 20 2024 11:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy2
Outperform0
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The 2 analysts offering 12 month price targets for IOL Chemicals and Pharmaceuticals Ltd. have a median target of 471.00, with a high estimate of 475.00 and a low estimate of 467.00. The median estimate represents a -3.15% decrease from the last price of 486.30.
High-2.3%475.00
Med-3.1%471.00
Low-4.0%467.00

Dividends

Historical dividend information is not available for IOL Chemicals and Pharmaceuticals Ltd.
Div growth (TTM)--
More ▼

Earnings history & estimates in INR

On Feb 07, 2023, earnings of 4.05 per share.
Average growth rate+891.23%
IOL Chemicals and Pharmaceuticals Ltd. reported annual 2024 earnings of 22.90 per share on May 14, 2024.
Average growth rate-25.98%
More ▼

Revenue history & estimates in INR

IOL Chemicals and Pharmaceuticals Limited had 1st quarter 2025 revenues of 5.02bn. This missed the 5.95bn estimate of the one analyst following the company. This was 10.80% below the prior year's 1st quarter results.
Average growth rate-2.80%
IOL Chemicals and Pharmaceuticals Limited had revenues for the full year 2024 of 21.33bn. This was 3.80% below the prior year's results.
Average growth rate+3.14%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.